publication venue for
- A practical guide for clinical and key opinion leader validation of health economic models. 26:473-476. 2023
- Impact of using the International Risk Scoring Tool on the cost-utility of palivizumab for preventing severe respiratory syncytial virus infection in Canadian moderate-to-late preterm infants. 26:630-643. 2023
- Association of factor expression levels with health-related quality of life and direct medical costs for people with haemophilia B. 25:386-392. 2022
- Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. 25:583-590. 2022
- Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthcare systems. 25:993-1004. 2022
- Hospitalization costs with degludec versus glargine U100 for patients with type 2 diabetes at high cardiovascular risk: Canadian costs applied to SAEs from a randomized outcomes trial. 24:1318-1326. 2021
- The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all. 22:478-487. 2019
- Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada. 22:390-401. 2019
- Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective. 22:45-52. 2019
- Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. 21:163-173. 2018
- Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. 20:435-442. 2017
- Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption. 20:337-344. 2017
- Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes. 19:630-644. 2016
- Cost-effectiveness analysis of oxycodone with naloxone versus oxycodone alone for the management of moderate-to-severe pain in patients with opioid-induced constipation in Canada. 19:277-291. 2016
- Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen for treatment of hepatitis C virus genotype 3 infection in Canada. 19:191-202. 2016
- Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis. 18:437-446. 2015
- Letter to the Editor. 17:445-445. 2014
- The cost implications of an early versus delayed invasive strategy in acute coronary syndromes: the TIMACS study. 17:415-422. 2014
- The cost effectiveness of palivizumab in congenital heart disease: a review of the current evidence. 16:115-124. 2013
- Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada. 15:3-14. 2012
- Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescue. 15:313-331. 2012
- The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study. 14:792-797. 2011
- Changing costs and the impact on RSV prophylaxis. 13:705-708. 2010
- The cost effectiveness of palivizumab: a systematic review of the evidence. 13:453-463. 2010
- The cost effectiveness of palivizumab in term Inuit infants in the Eastern Canadian Arctic. 12:361-370. 2009
- Cost comparison of four revascularisation procedures for the treatment of multivessel coronary artery disease. 11:119-134. 2008
- Cost comparison of four revascularisation procedures for the treatment of multivessel coronary artery disease: a commentary. 11:1-2. 2008
- Global assessment after bronchial thermoplasty: The patient's perspective. 10:37-46. 2006
- The humanistic burden of neuropathic pain in Canada. 10:23-36. 2006
- The economic burden of neuropathic pain in Canada. 9:55-68. 2006
- Cost of stroke in Canada: a 1-year prospective study. 8:147-167. 2005
- Self-reported dry eye symptoms in allergy patients using the disease impact questionnaire. 7:13-20. 2003